Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) – Stock analysts at HC Wainwright decreased their Q4 2022 earnings per share estimates for Talaris Therapeutics in a report released on Monday, January 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.50) for the quarter, down from their previous forecast of ($0.49). HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Talaris Therapeutics' current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Talaris Therapeutics' Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.51) EPS and FY2023 earnings at ($2.07) EPS.
Get Talaris Therapeutics alerts:Talaris Therapeutics Trading Up 18.5 %
Shares of TALS stock opened at $1.73 on Wednesday. The business's 50-day moving average price is $1.26 and its 200-day moving average price is $2.38. Talaris Therapeutics has a 12 month low of $0.89 and a 12 month high of $10.56. The firm has a market capitalization of $72.18 million, a price-to-earnings ratio of -1.04 and a beta of 1.98.
Talaris Therapeutics (NASDAQ:TALS – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).Hedge Funds Weigh In On Talaris Therapeutics
A number of hedge funds have recently made changes to their positions in TALS. SG Americas Securities LLC bought a new position in shares of Talaris Therapeutics during the third quarter worth about $27,000. Amalgamated Bank bought a new position in shares of Talaris Therapeutics during the first quarter worth about $31,000. Prospera Financial Services Inc bought a new position in shares of Talaris Therapeutics during the third quarter worth about $34,000. Commonwealth Equity Services LLC bought a new position in shares of Talaris Therapeutics during the third quarter worth about $34,000. Finally, Values First Advisors Inc. increased its holdings in Talaris Therapeutics by 29.9% in the fourth quarter. Values First Advisors Inc. now owns 39,891 shares of the company's stock worth $41,000 after purchasing an additional 9,176 shares in the last quarter. 65.43% of the stock is currently owned by institutional investors.
About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Featured Stories
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.